JP6220333B2 - 抗葉酸受容体アルファ抗体およびその使用 - Google Patents

抗葉酸受容体アルファ抗体およびその使用 Download PDF

Info

Publication number
JP6220333B2
JP6220333B2 JP2014520368A JP2014520368A JP6220333B2 JP 6220333 B2 JP6220333 B2 JP 6220333B2 JP 2014520368 A JP2014520368 A JP 2014520368A JP 2014520368 A JP2014520368 A JP 2014520368A JP 6220333 B2 JP6220333 B2 JP 6220333B2
Authority
JP
Japan
Prior art keywords
seq
antibody
frα
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014520368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524744A5 (enExample
JP2014524744A (ja
Inventor
ダニエル, ジョン オシャネシィ,
ダニエル, ジョン オシャネシィ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2014524744A publication Critical patent/JP2014524744A/ja
Publication of JP2014524744A5 publication Critical patent/JP2014524744A5/ja
Application granted granted Critical
Publication of JP6220333B2 publication Critical patent/JP6220333B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G01N33/57515
    • G01N33/5752
    • G01N33/57535
    • G01N33/57545
    • G01N33/5755
    • G01N33/57557
    • G01N33/5758
    • G01N33/5759
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014520368A 2011-07-15 2012-07-13 抗葉酸受容体アルファ抗体およびその使用 Active JP6220333B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161508444P 2011-07-15 2011-07-15
US61/508,444 2011-07-15
US201261604412P 2012-02-28 2012-02-28
US61/604,412 2012-02-28
US201261604954P 2012-02-29 2012-02-29
US61/604,954 2012-02-29
PCT/US2012/046672 WO2013012722A1 (en) 2011-07-15 2012-07-13 Anti-folate receptor alpha antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017190224A Division JP6526143B2 (ja) 2011-07-15 2017-09-29 抗葉酸受容体アルファ抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2014524744A JP2014524744A (ja) 2014-09-25
JP2014524744A5 JP2014524744A5 (enExample) 2015-08-06
JP6220333B2 true JP6220333B2 (ja) 2017-10-25

Family

ID=46516898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014520368A Active JP6220333B2 (ja) 2011-07-15 2012-07-13 抗葉酸受容体アルファ抗体およびその使用
JP2017190224A Active JP6526143B2 (ja) 2011-07-15 2017-09-29 抗葉酸受容体アルファ抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017190224A Active JP6526143B2 (ja) 2011-07-15 2017-09-29 抗葉酸受容体アルファ抗体およびその使用

Country Status (21)

Country Link
US (4) US8475795B2 (enExample)
EP (2) EP2731972B1 (enExample)
JP (2) JP6220333B2 (enExample)
CN (2) CN107011439B (enExample)
AU (3) AU2012284321C1 (enExample)
BR (1) BR112014001030A2 (enExample)
CA (1) CA2841725C (enExample)
CY (1) CY1120600T1 (enExample)
DK (1) DK2731972T3 (enExample)
ES (2) ES2663556T3 (enExample)
HR (1) HRP20180353T1 (enExample)
HU (1) HUE036929T2 (enExample)
LT (1) LT2731972T (enExample)
PL (1) PL2731972T3 (enExample)
PT (1) PT2731972T (enExample)
RS (1) RS56985B1 (enExample)
SG (1) SG10201605278PA (enExample)
SI (1) SI2731972T1 (enExample)
SM (1) SMT201800150T1 (enExample)
TR (1) TR201802838T4 (enExample)
WO (1) WO2013012722A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171234A (en) 2010-02-24 2019-10-04 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
EP3318273B1 (en) 2011-04-01 2019-08-21 ImmunoGen, Inc. Methods for increasing efficacy of folr1 cancer therapy
RS56985B1 (sr) * 2011-07-15 2018-05-31 Eisai R&D Man Co Ltd Antitela protiv alfa receptora folata i njihove upotrebe
HUE049693T2 (hu) 2012-08-31 2020-10-28 Immunogen Inc Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására
BR112015031950A2 (pt) 2013-06-20 2017-07-25 Morphotek Inc métodos para tratamento de câncer de ovário
LT3038650T (lt) 2013-08-30 2021-09-10 Immunogen, Inc. Antikūnai ir foliatų receptoriaus 1 nustatymo testai
AU2015255883A1 (en) * 2014-05-08 2016-10-27 Novodiax, Inc. Direct immunohistochemistry assay
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
MX387463B (es) 2014-11-20 2025-03-18 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer.
CN107074955B (zh) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
JP2018516244A (ja) * 2015-04-17 2018-06-21 モーフォテック, インコーポレイテッド 肺がんを処置するための方法
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
WO2018031968A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
KR102585143B1 (ko) 2016-08-12 2023-10-05 엘.이.에이.에프. 홀딩스 그룹 엘엘씨. 폴리글루타메이트화 항엽산 및 이의 용도
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
CN107793471B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽4及其应用
CN107446021B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽5及其应用
CN107353325B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽1及其应用
CN107446020B (zh) * 2017-07-28 2019-10-01 中国药科大学 叶酸受体α特异性结合肽2及其应用
MA50098A (fr) * 2017-09-05 2020-07-15 Immunogen Inc Procédés de détection du récepteur 1 des folates dans un échantillon provenant d'un patient
US12128046B2 (en) 2018-02-07 2024-10-29 L.E.A.F. Holdings Group Llc Alpha polyglutamated methotrexate and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
JP7490239B2 (ja) 2018-02-07 2024-05-27 エル.イー.エー.エフ. ホールディングス グループ エルエルシー ガンマポリグルタミン酸化ペメトレキセドおよびその使用
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
CN111867593A (zh) 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
EP3752155A4 (en) 2018-02-14 2022-03-16 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMATE METHOTREXATE AND USES THEREOF
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
JP7442822B2 (ja) 2018-02-14 2024-03-05 エル.イー.エー.エフ. ホールディングス グループ エルエルシー γポリグルタミン酸化テトラヒドロ葉酸およびその使用
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3091683A1 (en) 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
WO2020016661A2 (en) * 2018-07-09 2020-01-23 Multitude Inc. Antibodies specific to folate receptor alpha
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
US20230210989A1 (en) * 2020-06-03 2023-07-06 Kar Muthumani Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy
US20240226312A1 (en) * 2021-06-04 2024-07-11 Immunogen, Inc. Treatment of cancer in patients with soluble fr-alpha
WO2023009529A2 (en) 2021-07-28 2023-02-02 Trustees Of Boston University Novel polypeptides and uses thereof
WO2024104431A1 (zh) * 2022-11-16 2024-05-23 迈威(上海)生物科技股份有限公司 一种靶向FRα的抗体或其抗原结合片段及其应用
AR132931A1 (es) 2023-06-12 2025-08-13 Amgen Inc PROTEÍNAS DE UNIÓN A AGONISTAS DE RECEPTOR DE LINFOTOXINA b
CN117700556B (zh) * 2024-02-05 2024-04-12 苏州百道医疗科技有限公司 一种抗FRα小鼠单克隆抗体及其应用
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段
CN120554514B (zh) * 2025-07-29 2025-12-05 合肥综合性国家科学中心大健康研究院 一种靶向人的叶酸受体α的单克隆抗体
CN120842412B (zh) * 2025-09-23 2025-12-05 合肥综合性国家科学中心大健康研究院 一种靶向人的叶酸受体α的单克隆抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20080131366A1 (en) 2003-03-17 2008-06-05 Manohar Ratnam Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy
CA2526647A1 (en) 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
AU2006230219A1 (en) 2005-03-30 2006-10-05 Endocyte, Inc. Method for cancer prognosis using cellular folate vitamin receptor quantification
US20060239910A1 (en) 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7754698B2 (en) 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
FR2918994B1 (fr) 2007-07-20 2012-10-19 Rhodia Operations Formulations de diesters d'acide carboxylique et leur utilisation pour le traitement de materiaux.
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
SG10201509145XA (en) 2010-11-05 2015-12-30 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
JP2014508165A (ja) 2011-03-02 2014-04-03 モルフォテック、インク. 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
RS56985B1 (sr) * 2011-07-15 2018-05-31 Eisai R&D Man Co Ltd Antitela protiv alfa receptora folata i njihove upotrebe

Also Published As

Publication number Publication date
LT2731972T (lt) 2018-03-26
JP2018029605A (ja) 2018-03-01
SMT201800150T1 (it) 2018-05-02
US9599621B2 (en) 2017-03-21
AU2017202365B2 (en) 2018-06-28
CY1120600T1 (el) 2019-12-11
AU2012284321A1 (en) 2014-02-06
CN107011439B (zh) 2020-11-10
ES2663556T3 (es) 2018-04-13
US8475795B2 (en) 2013-07-02
SG10201605278PA (en) 2016-08-30
ES2824498T3 (es) 2021-05-12
EP2731972B1 (en) 2017-12-20
US20130017195A1 (en) 2013-01-17
US20170168078A1 (en) 2017-06-15
CN107011439A (zh) 2017-08-04
CA2841725C (en) 2021-03-09
EP2731972A1 (en) 2014-05-21
US20130183299A1 (en) 2013-07-18
HUE036929T2 (hu) 2018-08-28
TR201802838T4 (tr) 2018-03-21
DK2731972T3 (en) 2018-03-12
US10101343B2 (en) 2018-10-16
AU2012284321C1 (en) 2017-07-13
WO2013012722A1 (en) 2013-01-24
RS56985B1 (sr) 2018-05-31
PT2731972T (pt) 2018-03-09
EP3330291B1 (en) 2020-09-02
AU2012284321B2 (en) 2017-03-09
US20140341897A1 (en) 2014-11-20
CN103998467B (zh) 2016-12-14
AU2018236755B2 (en) 2019-11-14
EP3330291A1 (en) 2018-06-06
SI2731972T1 (en) 2018-04-30
AU2017202365A1 (en) 2017-04-27
US8834877B2 (en) 2014-09-16
JP6526143B2 (ja) 2019-06-05
BR112014001030A2 (pt) 2017-07-04
CA2841725A1 (en) 2013-01-24
HRP20180353T1 (hr) 2018-04-06
CN103998467A (zh) 2014-08-20
JP2014524744A (ja) 2014-09-25
AU2018236755A1 (en) 2018-10-18
PL2731972T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
JP6220333B2 (ja) 抗葉酸受容体アルファ抗体およびその使用
JP7072571B2 (ja) 抗葉酸受容体アルファ抗体およびその使用
JP6591580B2 (ja) Tem−1診断用抗体
TW200823293A (en) Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease
TWI782000B (zh) 抗gpr20抗體、其製造方法及其應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170929

R150 Certificate of patent or registration of utility model

Ref document number: 6220333

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250